RT Journal Article
SR Electronic
T1 SARS-CoV-2 serological testing using electrochemiluminescence reveals a rapid onset of seroconversion in severe COVID-19 patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.28.20141838
DO 10.1101/2020.06.28.20141838
A1 Munitz, A
A1 Edry-Botzer, L
A1 Itan, M
A1 Tur-Kaspa, R
A1 Dicker, D
A1 Markovitch, D
A1 Goren, M
A1 Mor, M
A1 Lev, S
A1 Gottesman, T
A1 Muhsen, K
A1 Cohen, D
A1 Stein, M
A1 Qimron, U
A1 Freund, N
A1 Wine, Y
A1 Gerlic, M
YR 2020
UL http://medrxiv.org/content/early/2020/06/30/2020.06.28.20141838.1.abstract
AB Despite ongoing efforts to characterize the host response toward SARS-CoV-2, a major gap in our knowledge still exists regarding the magnitude and duration of the humoral response. We report the development of a rapid, highly specific and sensitive electrochemiluminescent assay for detecting IgM, IgA, and IgG antibodies toward two distinct SARS-CoV-2 antigens namely, the receptor binding domain (RBD) and the nuclear protein (NP). Whereas IgM antibodies toward RBD were detected at early stages of the disease, IgM antibodies against NP did not develop. Analysis of the antibody response in mild versus moderate/severe patients revealed a rapid onset of IgG and IgA antibodies, specifically in moderate/severe patients. Finally, we observed a marked reduction in IgM/IgA antibodies and to lesser extent, IgG, over time. We provide a comprehensive analysis of the human antibody response, and has major implications on our understanding and monitoring of SARS-CoV-2 infections, as well as finding effective vaccines.One Sentence Summary Using a newly developed assay to detect anti-SARS-Cov-2 IgM, IgG and IgA antibodies we reveal a rapid onset of IgG and IgA antibodies towards distinct viral antigens, specifically in moderate/severe COVID-19 patients,Competing Interest StatementAM and MG filed a patent application regarding antibodies that were presented in this studyFunding StatementA.M. acknowledges funding from the US-BSF grant #2011244, ISF grant #886/15, ICRF, and the Cancer Biology Research Center, Tel Aviv University. M.G. acknowledges funding from Alpha-1 foundation grant #615533 and US-BSF grant #2017176, ISF grant #818/18, the Recanati Foundation, and the Varda and Boaz Dotan Research Center in Hemato-Oncology. A.M and M.G acknowledge a development grant from Biological Industries, Beit Haemek, Israel; U.Q. acknowledges funding from CoG-ERC grant #818878. N.T.F acknowledges funding from ISF grant # 1422/18 and Israeli Innovation Authority # grant 65029 and the Milner Foundation. Y. W acknowledges funding from US-BSF grant #2017359 and ISF grant #1282/17.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All experiments were reviewed and approved by the Helsinki committee (IRB#RMC-0265-20) and were performed according to their regulations and guidelines.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data will be available upon request